PRESS RELEASE : Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

DGAP-News: Evotec SE / Key word(s): Miscellaneous 
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 
2021-04-19 / 08:31 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY 
    ASSET EVT801 
  . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC 
  . EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ("CMC") 
  . EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO 
    RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES 
Hamburg, Germany, 19 April 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered 
into both a licensing and master service agreement with Kazia Therapeutics Limited ("Kazia", ASX: KZA; NASDAQ: KZIA), 
an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive 
worldwide license for research, development and commercialisation of Evotec's oncology project EVT801. 
EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor 
VEGFR3, originally developed within Evotec's partnership with Sanofi. The high selectivity of EVT801 for VEGFR3 over 
other VEGF receptors differentiates the compound from other small-molecule multi-kinase inhibitors that target multiple 
VEGF receptors, which are associated with significant toxicity. EVT801 provides the potential to specifically 
antagonise VEGFR3 to combine high efficacy both against the primary tumour and lymphatic-borne metastases with a highly 
favourable toxicology profile. 
Kazia seeks to clinically evaluate EVT801 both as a single agent and in combination with immunotherapy in a set of 
specific oncology indications. Evotec will manage the Phase I trial under the full sponsorship of Kazia. Kazia will be 
responsible for any subsequent clinical evaluation and commercialisation of EVT801. 
Evotec receives a small upfront payment as well as further payments for continued support progressing EVT801 into the 
clinic and beyond, e.g. for biomarker development and CMC. Additionally, Evotec is eligible to receive clinical and 
commercial milestones of more than EUR 300 m as well as tiered high single-digit royalties on the net sales of EVT801, 
which will be shared with Sanofi, Evotec's partner for the discovery and early development of EVT801. 
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to enter this licensing agreement with 
Kazia, who have a strong track record of clinical expertise in oncology. EVT801 comes with a comprehensive pre-clinical 
data package, very well-characterised pharmacology, and a clear mechanistic understanding that can inform rational 
selection of target populations and therapeutic combinations. In addition to a great asset, Evotec provides Kazia with 
a world-class team to continue progression into the clinic. We look forward to working with Kazia, to make EVT801 
available to patients globally, thus providing a new treatment option for their severe unmet medical needs." 
Dr James Garner, Chief Executive Office of Kazia, said: "We are delighted to add this tremendously exciting new 
compound to the Kazia pipeline. Evotec have done first-class work in the early development of EVT801, and the 
preclinical data package is exceptionally strong. Our intention is to fast track a phase I clinical trial of the drug, 
which we expect to commence in CY2021." 
ABOUT KAZIA THERAPEUTICS LIMITED 
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, 
Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being 
developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed 
from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 
2021. Seven additional studies are active in other forms of brain cancer. Paxalisib was granted Orphan Drug Designation 
for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 
2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for 
DIPG in August 2020. In March 2021, Kazia licensed Greater China rights for paxalisib to Simcere Pharmaceutical 
Company. For more information, please visit www.kaziatherapeutics.com. 
ABOUT EVOTEC SE 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative 
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and 
venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and 
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the 
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has 
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies 
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare 
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned 
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple 
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo 
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us 
on Twitter @Evotec. 
FORWARD-LOOKING STATEMENTS 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this 
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of 
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ 
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
Media Contact Evotec SE: 
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: [phone], 
[e-mail] 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: [phone], [e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-19 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1185965 
 
End of News   DGAP News Service 
=------------ 

1185965 2021-04-19

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1185965&application_name=news

(END) Dow Jones Newswires

April 19, 2021 02:31 ET (06:31 GMT)